Mark Benveniste: Healthcare Professional
Healthcare Revenue Consulting, Business Development (B2B and B2C), Marketing and Sales Training
The time is now to use pharmacogenetic testing to prevent opioid-related deaths. Many deaths are caused by overdoses when in fact the patient took the medications according to the dosing schedules. Poor metabolizers can “store” doses such that an overdose can occur when the drugs are released into the patients’ system.
Source: Opioid-Related Deaths Possibly Prevented By Gene Testing – Clinical Chemistry – Labmedica.com
The authors concluded that the combination of the circulating tumor DNA (ctDNA) and protein markers was superior to any single marker. Moreover, the combination detected nearly two-thirds of pancreatic cancers that had no evidence of distant metastasis at the time of surgical resection. The strategy may represent an approach to detect cancers of many types at an earlier stage.
Source: Combination Liquid Biopsy Diagnoses Early Cancer – Pathology – Labmedica.com
Another great little article on the future of pharmacy and the value of Pharmacogenetics testing. Worth the read to learn how patients benefit from testing which medications work and which ones don’t work with their genetics.
Mark Dunnenberger, PharmD, Program Director for Pharmacogenomics at the NorthShore Center for Personalized Medicine said, “It can bring a lot of value to the patient.”
Read on…
Pharmacogenetics is moving into the community pharmacy. A patient’s DNA sample is taken in the pharmacy, sent to a lab, and in a couple of weeks, the patient, pharmacist, and health-care provi
Source: Pharmacogenetics in the Community Pharmacy | Drug Topics